What is Foundayo and is orforglipron a peptide?
Foundayo is the brand name for orforglipron, an oral GLP-1 receptor agonist FDA approved in April 2026 for chronic weight management in eligible adults. Orforglipron is a small molecule, not a peptide. 1, 2
GLP-1 receptor agonist describes a target in the body, not one chemical structure. A medication can act on that receptor without being a peptide.
Foundayo’s approval applies to adults with obesity or overweight with a weight-related condition, alongside diet and physical activity. A clinician must review the full label and individual history to determine suitability.
Is it oral semaglutide?
No. Orforglipron and semaglutide are different medications. Their product instructions, studied regimens, and labels cannot be exchanged.
Does being a pill make it risk-free?
No. Foundayo has contraindications, warnings, interactions, and potential adverse effects. Review other medications and relevant medical history with the prescriber rather than assuming a tablet has fewer clinical requirements.
Bottom line
Foundayo expands the approved medication options. Its nonpeptide structure does not remove the need for individualized prescribing and follow-up.
See how Sipra weight care worksFrequently asked questions
Related questions
Lose weight with a plan made just for you
- Same-day doctor visits and prescriptions
- Semaglutide, tirzepatide & other GLP-1s
- FSA & HSA eligible with all plans
From price shown is the 12-month plan rate. Prices may vary.
Was this helpful?